The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

In 2023, Moderna started a phase 1/2 study of an experimental pandemic influenza vaccines collectively known as mRNA-1018, which are designed to provide protection against H5 and H7 avian ...

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

Funding for a potential bird flu vaccine was recently pulled. Moderna expects to end 2025 with $6bn in cash. And analysts see revenue growth resuming in 2026, rising 16% to $2.4bn. Then up another 25% ...

HHS Sec. RFK Jr. says Dr. Anthony Fauci is likely liable for the origins of the COVID-19 pandemic, calling for a nationwide ...

Trump and Musk reignite feud over tax bill, stocks end first half at records, Moderna flu vaccine achieves promising results, ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...